Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
The summary for the Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional): Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Federal Grant Title: | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education, Environment, Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-24-294 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.113, 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.866, 93.867 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | August 18th, 2027 |
Original Application Deadline: | August 18th, 2027 |
Posted Date: | October 1st, 2024 |
Creation Date: | October 1st, 2024 |
Archive Date: | September 23rd, 2027 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | October 1st, 2024 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- • Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
- • Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- • CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational E...
- • Environmental Health Disparities Centers (P50) Clinical Trial Optional
- • Outstanding New Environmental Scientist Award (ONES)
- • Environmental Health Sciences Core Center Grants
- • Leiomyomata Uteri: Basic Science and Translational Research
- More Grants from the National Institutes of Health
- • CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research ...
- • NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Cl...
- • Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Cl...
- • Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-te...
- • Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)